Protagenic Therapeutics Inc. announced that the Japanese Patent Office has granted Patent JP 7714571B on July 18, 2025. This patent, which will remain in effect until March 31, 2041, is a key asset in the company's pipeline. It covers a modified stilbenoid and provides exclusivity to specific compounds, formulations, and their medical use in the treatment of epilepsy and seizures. This grant follows a similar patent granted in the UK and marks a significant step in Protagenic Therapeutics' innovative development efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021552), on July 30, 2025, and is solely responsible for the information contained therein.